Regeneron Pharmaceuticals, Inc. (LON:0R2M)
London
· Delayed Price · Currency is GBP · Price in USD 640.83
+4.10 (0.64%)
At close: Mar 28, 2025
Regeneron Pharmaceuticals Revenue
In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B USD with 8.27% growth. Regeneron Pharmaceuticals had revenue of $3.79B in the quarter ending December 31, 2024, with 10.33% growth.
Revenue
$14.20B
Revenue Growth
+8.27%
P/S Ratio
n/a
Revenue / Employee
$940.16K
Employees
15,106
Market Cap
52.69B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.19B |
| GSK plc | 31.38B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Genus | 671.60M |
Regeneron Pharmaceuticals News
- 3 days ago - Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD - GlobeNewsWire
- 3 days ago - Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD) - GlobeNewsWire
- 5 days ago - Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025 - GlobeNewsWire
- 6 days ago - Lawsuit Notice: Investors who hold Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares should contact the Shareholders Foundation - GlobeNewsWire
- 17 days ago - Regeneron falls after appeals court ruling in Eylea case - Seeking Alpha
- 17 days ago - Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again? - Seeking Alpha
- 19 days ago - Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem - PRNewsWire
- 19 days ago - Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem - GlobeNewsWire